Two ways to own the AI biotech trade
AI biotech stocks split into two broad business models, and the distinction matters more than the ticker. The first is the royalty model: a company licenses its platform or a discovered asset to a big pharma partner, collects upfront and milestone payments, and eventually earns royalties on any drug that reaches market. The second is the platform model: the company runs the full pipeline itself, from discovery to clinical trials, and keeps more of the upside while bearing more of the cost.
Alexander Green’s Oxford Club pitch for “my number one microcap for today’s market” points at a royalty-style story. He describes a company where big pharmaceutical partners use its AI to design new drugs, then handle testing, approval, and marketing while the company “simply collect[s] royalties all along the way.” The example behind the tease is Absci, an AI-powered drug discovery firm, and the framing is accurate as far as it goes. Royalties are genuinely how this corner of biotech works. The timing is the part the ad compresses.
Why the royalty model exists
The royalty model exists because drug development is brutally expensive and slow. A single drug can cost more than $2 billion and take a decade to bring to market, and most candidates fail. Big pharma companies have the capital and the regulatory muscle to run trials, but they are constantly shopping for new molecules to fill their pipelines. A small AI firm that can produce promising candidates faster has something pharma wants to buy, and the natural deal is a license with milestones and royalties rather than a full acquisition.
We explain the mechanics of that structure in our best royalty stocks explainer. The key idea is that a royalty stream is a claim on future drug revenue, and the value of that claim depends entirely on drugs actually reaching market. A company with real partners and a clinical-stage asset is far closer to that point than one with only a platform and a pitch deck.
The platform model, and why it is riskier
The platform model keeps everything in-house. The company discovers, develops, and commercializes its own drugs, which means it captures the full value of a win but also absorbs the full cost of the failures in between. That is the model behind most of the headline AI drug discovery names, and it is why the sector trades with such wide swings: a single clinical readout can double or halve a stock.
The tradeoff is capital. Running trials requires cash, and early-stage biotech companies raise it by selling stock, which dilutes existing holders. The royalty model shifts some of that burden to the pharma partner, which is one reason it appeals to retail investors who do not want to fund a decade of trials themselves.
The part the pitch skips
AI changes the discovery step, not the clinical step. An AI model can design a promising drug candidate in weeks where traditional screening took years, but that candidate still has to pass through the same years of human trials before it becomes a product. The speedup is real and concentrated at the front of the pipeline; the back of the pipeline, the part that actually generates revenue, moves at the same regulatory pace it always has.
That gap explains why AI biotech stocks are so hard to value. The market prices them as if the discovery speedup will flow straight through to revenue, but the trials in between are a fixed cost of time and capital that no algorithm shortens. A company can have a genuinely better discovery engine and still be five or more years from a royalty check. Understanding that distinction, discovery speed versus clinical time, is the single most useful thing to know before buying any AI biotech stock.
How to tell which one you are buying
The quickest test is the revenue line. A royalty-style company tends to have lumpy, milestone-driven revenue from a handful of partners, because its income arrives when a partner hits a development milestone or a drug launches. A platform company burns cash to fund its own pipeline and shows little or no product revenue until something gets approved.
Neither model is better in the abstract. The royalty model trades upside for capital efficiency and partner validation, while the platform model trades safety for full ownership of the outcome. The honest way to approach AI biotech stocks is to name which model you are buying, check whether the partners or the pipeline are real, and then price the stock against the specific catalysts in front of it, not against a slogan. Our AI drug discovery companies guide maps the leading names by model.
Ready to see the research? Click here to access Alexander Green’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.